سعر ارتينيبسا 40مجم/0.01مجم/مل حقن 2025

Articaine hydrochloride 40 mg/ml with epinephrine 0.01 mg/ml (1:100,000) solution for dental local anaesthesia (1.8 ml cartridges per the Spanish SmPC), manufactured by Inibsa (Spain), listed in Egypt with Wedjat Pharma; Egyptian pack size not stated.

• Local anaesthesia (infiltration and nerve block) in dentistry during complicated procedures requiring prolonged anaesthesia.Population: Adults and children 4 years of age and olderInibsa Dental S.L.U. (marketing authorisation holder, inibsadental.com)
• Local, infiltrative or conductive anaesthesia in both simple and complex dental procedures.Population: Adults and children 4 years of age and olderDailyMed (U.S. National Library of Medicine)

• Adverse reactions are rare and mostly dose-related: CNS effects (e.g. metallic taste, tinnitus, dizziness, agitation, convulsions), bradycardia and hypotension, paraesthesia or nerve injury, allergic reactions; epinephrine-related palpitations, tachycardia and hypertension; methaemoglobinaemia at high doses; facial nerve paralysis has been reported.International label, same product · Inibsa Dental S.L.U. (marketing authorisation holder, inibsadental.com)
• Most common adverse reactions (>2%): headache and pain.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Post-marketing: persistent paraesthesia of lips, tongue and oral tissues (mainly after mandibular nerve blocks), ischaemic injury or necrosis at the injection site, and ocular muscle paralysis/visual disturbances.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Hypersensitivity to articaine, epinephrine, any excipient, or amide-type local anaesthetics; severe cardiac conduction disorders (e.g. grade II/III AV block, pronounced bradycardia); acute decompensated heart failure; severe hypotension; known cholinesterase deficiency; haemorrhagic diathesis (particularly with nerve block); injection into inflamed areas.International label, same product · Inibsa Dental S.L.U. (marketing authorisation holder, inibsadental.com)
• Due to epinephrine: unstable angina, recent myocardial infarction, recent coronary artery bypass surgery, refractory arrhythmias or paroxysmal tachycardia, untreated/uncontrolled severe hypertension, untreated/uncontrolled congestive heart failure, and concomitant MAO inhibitors or tricyclic antidepressants.International label, same product · Inibsa Dental S.L.U. (marketing authorisation holder, inibsadental.com)
• Due to the sulphite (sodium metabisulfite) excipient: sulphite allergy and severe bronchial asthma.International label, same product · Inibsa Dental S.L.U. (marketing authorisation holder, inibsadental.com)

• Use with special caution in severe renal impairment, angina pectoris, arteriosclerosis, significant coagulation disorders, thyrotoxicosis, narrow-angle glaucoma, diabetes, lung disease (especially allergic asthma), phaeochromocytoma, liver disease and epilepsy.International label, same product · Inibsa Dental S.L.U. (marketing authorisation holder, inibsadental.com)
• Numbness of soft tissues: patients (especially children) may bite lips, cheek or tongue; avoid eating until sensation returns. Accidental intravascular injection must be avoided (aspiration).International label, same product · Inibsa Dental S.L.U. (marketing authorisation holder, inibsadental.com)
• Accidental intravascular injection may cause cardiac arrhythmias or cardiac arrest; aspirate before injecting.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• MAO inhibitors and tricyclic antidepressantsMay intensify the cardiovascular effects of epinephrine (contraindicated combination).Inibsa Dental S.L.U. (marketing authorisation holder, inibsadental.com)
• Oral antidiabeticsEpinephrine may inhibit insulin release and reduce the effect of oral antidiabetics.Inibsa Dental S.L.U. (marketing authorisation holder, inibsadental.com)
• PhenothiazinesMay reduce the pressor effect of epinephrine.Inibsa Dental S.L.U. (marketing authorisation holder, inibsadental.com)

• Insufficient human data in pregnancy; use only after careful benefit-risk assessment.International label, same product · Inibsa Dental S.L.U. (marketing authorisation holder, inibsadental.com)
• No adequate and well-controlled studies in pregnant women; in rabbits fetal deaths and skeletal variations occurred at about 4 times the maximum recommended human dose. Use during pregnancy only if the potential benefit justifies the potential risk to the fetus.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Breast-feeding can be resumed after anaesthesia; the first breast milk after the procedure should be discarded as a precaution.International label, same product · Inibsa Dental S.L.U. (marketing authorisation holder, inibsadental.com)

• Articaine hydrochloride: Blocks the generation and conduction of nerve impulses by reducing sodium permeability of the nerve membrane (label).
• Epinephrine (adrenaline): Local vasoconstriction slows systemic absorption, prolonging and intensifying the anaesthetic effect (label).